Intercept Pharma (ICPT) Briefing Docs Raise New Questions, But All Appear Addressable - Leerink
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Dell shares surge on record AI server bookings
- 'No panic anywhere' may be the problem, BofA strategists warn
- AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
- Kroger cuts same-store sales outlook, keeps earnings guidance
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
PBC Committee Opens The Door to $2.2B Opportunity For Intercept Pharma (ICPT) - Wedbush
April 6, 2016 7:50 AM EDTWedbush analyst, Liana Moussatos, reviewed the FDA's briefing documents for Intercept Pharmaceuticals (NASDAQ: ICPT) obeticholic acid (OCA) in primary biliary cholangitis (PBC) Advisory Committee meeting and does not see any major red flags for approval.
As the analyst anticipated, the FDA appears to be focused on the validity of the primary endpoints (ALP... More
Intercept Pharmaceuticals (ICPT) Briefing Docs 'Mostly In-Line' - FBR Capital
April 5, 2016 11:07 AM EDTFBR Capital analyst Vernon Bernardino reiterated a Market Perform rating and $192 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) the FDA released briefing documents ahead of the April 7 meeting of its Gastrointestinal Drugs Advisory Committee (GIDAC) to discuss ICPT's new New Drug Application (NDA) for approval to use obeticholic acid (OCA), which is the company's investigational treatment for primary... More
Baird Maintains Bullish View on Intercept Pharmaceuticals (ICPT) Following Positive Briefing Docs
April 5, 2016 10:32 AM EDTBaird analyst Brian Skorney reiterated an Outperform rating and $332 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) following positive FDA briefing documents.
Skorney commented, "Though we admit being scared by FDA's three-month delay, today's briefing docs are, what's the word?... More
Wells Fargo Upgrades Intercept Pharmaceuticals (ICPT) to Outperform
April 5, 2016 9:02 AM EDTWells Fargo upgraded Intercept Pharmaceuticals (NASDAQ: ICPT) from Market Perform to Outperform.
For an analyst ratings summary and ratings history on Intercept Pharmaceuticals click here. For more ratings news on Intercept Pharmaceuticals click here.
Shares of Intercept Pharmaceuticals closed at $133.55 yesterday.
... MoreIntercept Pharma (ICPT) FDA Briefing Documents Posted
April 5, 2016 8:01 AM EDTIntercept Pharma (NASDAQ: ICPT) FDA briefing documents posted. LINK
... MoreBiotech Seen Grinding Higher, Says RBC Capital (IBB)
April 4, 2016 1:52 PM EDTRBC analyst Michael J. Yee doesn't thinks biotech will make a v-shaped rally, but he expects the sector to grind higher this year. In the note, Yee also touched on several individual stocks -- Celgene (NASDAQ: CELG), Biogen (NASDAQ: BIIB), Vertex Pharma (NASDAQ: VRTX), BioMarin Pharma (NASDAQ: BMRN), and Intercept Pharma (NASDAQ: ICPT).
"While we are not expecting an easy V-shaped rally, we do continue to... More
